Why paying for paediatric medicines is different
Health technology assessment was built around adult trials and adult lives. Children’s medicines strain almost every assumption it relies on.
In brief
Why health technology assessment struggles with children’s medicines: small trials, hard-to-measure quality of life and lifetime benefits.
Getting a children’s medicine licensed is only half the battle. In most health systems it then has to pass a health technology assessment (HTA), the process by which payers decide whether a medicine offers enough benefit for its price. For paediatric products, that second hurdle can be the harder one.
Small trials, big uncertainty
HTA bodies prize robust comparative evidence. Paediatric trials are often small, single-arm or reliant on extrapolation from adults, which leaves wide uncertainty around how much benefit a child will actually gain. Uncertainty tends to be priced against the manufacturer.
Measuring quality of life in children
Many HTA systems, including NICE in England, rely on quality-adjusted life years. Measuring quality of life in young children is genuinely difficult. Instruments designed for adults do not work for infants, children’s own reports change with age, and proxy reports from parents can differ from what a child would say. Child-specific versions of standard questionnaires exist, but there is no settled method for turning their results into the utility values that cost-effectiveness models need.
Lifetime benefits, upfront prices
Treatments given early in life, particularly one-off gene therapies, can deliver benefits that stretch across decades. Models must extrapolate far beyond the trial data, and the choice of discount rate can swing the result. A high upfront price paid now for benefits realised over sixty years looks very different depending on those assumptions.
How payers are adapting
Several tools have emerged. Managed access agreements let a medicine be used while more data are collected. Outcomes-based contracts tie part of the payment to whether the treatment works for each patient. Instalment models spread the cost of one-time therapies over several years.
None of these resolves the underlying tension, but they have made it possible for some high-cost paediatric medicines to reach patients while the evidence matures.
